PGD 2 4 is a lipid mediator involved in sleep (1, 2) and inflammatory responses (3). PGD 2 activates two different types of receptors (i.e. DP 1 (4) and DP 2 (also known as CRTH2 (5))). PGD 2 regulates sleep (2, 6) and pain (7) via DP 1 receptors in the central nervous system. This prostanoid also causes contraction of airway smooth muscle via DP 1 receptors (8) and mediates chemotaxis of eosinophils and basophils into the lung via DP 2 receptors (9) in the periphery. Therefore, PGD 2 coordinately regulates allergic reactions, especially airway inflammation, via these two receptors (9) . PGD 2 is formed by the following sequence of enzyme reactions after cell activation: 1) cytosolic phospholipase A 2 is translocated to the endoplasmic reticulum and perinuclear membranes in a Ca 2ϩ -dependent manner, where it cleaves arachidonic acid from the membrane phospholipids; 2) arachidonic acid is converted to PGH 2 , a common precursor of various prostanoids, by the membrane-bound cyclooxygenases (COXs); and 3) PGH 2 is further isomerized to PGD 2 by PGD synthase (PGDS). There are two distinct types of PGDS, namely lipocalin-type PGDS (L-PGDS) (10 -13) and hematopoietic PGDS (H-PGDS) (14 -16) .
L-PGDS contributes to the production of PGD 2 in the central nervous system (10, 17, 18) , ocular tissues (19) , cardiovascular systems (20) , and male genital organs (21) of various mammals and is involved in the regulation of non-rapid eye movement sleep (2, 22) , sex determination (23) , protection of atherosclerosis (24, 25) , and adipogenesis (26) . L-PGDS is secreted into the cerebrospinal fluid (CSF) (27, 28) , seminal plasma (29, 30) , and plasma (20) as ␤-trace, a major protein in human CSF (31) .
L-PGDS is the only enzyme among the members of the lipocalin gene family (11) , which is composed of various secretory proteins involved in binding and transporting small lipophilic substances, such as retinoids and thyroids (32) . L-PGDS also binds retinoic acid, retinal (33) , biliverdin (34) , bilirubin (34) , gangliosides (35) , and amyloid ␤ peptides (36) with high affinities of K d ϭ 20 -200 nM, indicating that L-PGDS may act as a transporter protein of these lipophilic compounds and as an endogenous chaperon to prevent amyloid ␤ aggregation. On the other hand, H-PGDS is the first known vertebrate homolog of the class of glutathione S-transferases (37) . Because both of these enzymes have evolved from different origins to acquire the same catalytic function, these two enzymes are considered to be a new example of functional convergence (38, 39) .
Inorganic quadrivalent selenium (Se 4ϩ ) compounds are known to be noncompetitive and reversible inhibitors of L-PGDS (40) and to inhibit the sleep of animals in a time-and dose-dependent manner after infusion into the third ventricle of rats or an intraperitoneal injection into mice (2, 41) . However, no organic inhibitor of L-PGDS has been reported until now. We recently found that 4-benzhydryloxy-1-(3-(1H-tetrazol-5-yl)-propyl)-piperidine (HQL-79; Fig. 1 ) is an orally active and selective inhibitor of H-PGDS (42) . Because L-PGDS catalyzes the same reaction as H-PGDS, we suspected that some derivative(s) of HQL-79 might have an inhibition activity toward L-PGDS. Among various tetrazol compounds, we found that 4-dibenzo[a,d]cyclohepten-5-ylidene-1-[4-(2H-tetrazol-5-yl)-butyl]-piperidine (AT-56; Fig. 1 ) is a specific inhibitor of L-PGDS (43), having a higher potency and biological availability than seleno-compounds in vivo.
In the present study, we characterized AT-56 and found it to be a competitive inhibitor of L-PGDS against PGH 2 by kinetic analysis and also used NMR analysis to determine the binding mode of AT-56 to L-PGDS. In addition we found that AT-56 inhibited the production of PGD 2 by L-PGDS-expressing cultured cells, H-PGDS gene knock-out (KO) mice, and human L-PGDS overexpressing transgenic (TG) mice.
EXPERIMENTAL PROCEDURES
Chemicals-AT-56 was a generous gift from TAIHO Pharmaceutical Company (Saitama, Japan). AT-56 was dissolved in DMSO for in vitro experiments and in 0.5% methylcellulose for oral administration to mice, due to its high lipophilicity. In aqueous solution, the maximum solubility of AT-56 was determined to be 90 M in saline containing 1% DMSO and 260 M in 10% DMSO, as determined by UV absorption at 287 nm. Other reagents were purchased from Sigma or Wako (Osaka, Japan), unless otherwise specified.
Purification of Human CSF L-PGDS (␤-Trace) and Recombinant Mouse L-PGDS-Human
CSF L-PGDS (␤-trace) was purified from human CSF, which was donated by Dr. M. Mase (Nagoya City University Hospital), as reported (36) .
The full-length cDNA for mouse L-PGDS, which is composed of 189 amino acid residues (GenBank TM accession number X89222), was ligated into the BamHI-EcoRI site of the expression vector pGEX-2T plasmid (GE Healthcare). The N-terminal 22-amino acid residues of the signal peptide were deleted, and the C89A/C186A-and W54A-substituted recombinant enzymes were expressed in Escherichia coli DH5␣ (TOYOBO, Osaka, Japan). Site-directed mutagenesis was performed by using a QuikChange site-directed mutagenesis kit (Stratagene, La Jolla, CA). The recombinant enzymes retained PGDS activity comparable with that of the wild-type enzyme and were stable for long term use. The mutated L-PGDS was expressed as a GSH transferase fusion protein, purified by column chromatography with GSH-Sepharose 4B (GE Healthcare), and eluted from the column by incubation with thrombin (100 units/100 l of resin), as reported previously (44) . The recombinant protein was further purified to apparent homogeneity by gel filtration chromatography with Superdex 75 in 5 mM Tris/HCl (pH 8.0).
Fluorescence Quenching Assays-13-cis-Retinoic acid and AT-56 were dissolved in DMSO to give a 2 mM stock solution. Various concentrations of 13-cis-retinoic acid and AT-56 in 10 l of DMSO were added to the L-PGDS solution in 990 l of 5 mM Tris/HCl (pH 8.0). After incubation at room temperature for 60 min, the intrinsic tryptophan fluorescence was detected with an FP-750 spectrofluorometer (JASCO, Tokyo, Japan) at an excitation wavelength at 282 nm and an emission wavelength at 338 nm, as reported previously (44) .
Enzyme Activity Assays-Enzyme activities of L-PGDS (45), H-PGDS (46) , and microsomal PGE synthase (m-PGES-1 (47)) were measured with 10 M [1-
14 C]PGH 2 as a substrate in 100 mM Tris-HCl, pH 8.0, in the presence of 1 mM GSH, 0.1 mg/ml IgG, and 10% DMSO. The activities of COX-1 and COX-2 were measured as described earlier (48) with 50 M [1-
14
C]arachidonic acid (PerkinElmer) used as a substrate in 100 mM TrisHCl, pH 8.0, containing 2 M hematin, 5 mM L-tryptophan, 0.1 mg/ml IgG, and 10% DMSO. The products were separated by thin layer chromatography. The conversion rate from 14 C-labeled substrate to 14 C-labeled products was calculated by using an imaging plate system (Fuji Film, Tokyo, Japan). The kinetic constants were determined by Lineweaver-Burk plots prepared with SigmaPlot software (version 10.0 for Windows; Systat Software, Inc.).
NMR Titration Experiment-The NMR samples of mouse L-PGDS were prepared in a mixture of 50 mM sodium phosphate in 75% H 2 O, 15% D 2 O, 10% DMSO at pH 7.0, as reported previously (49) . The protein concentration was adjusted to ϳ1 mM in a 5-mm microcell NMR tube (Shigemi, Tokyo, Japan) for NMR experiments. NMR experiments were performed at 27.5°C by using an INOVA600 spectrometer (Varian, Palo Alto, CA) equipped with shielded gradient triple resonance probes (49) .
The binding of L-PGDS to AT-56 was monitored by NMR titration of 15 5 /well) cells were seeded into multiplates and cultured in Dulbecco's modified Eagle's medium supplemented with 10% heat-inactivated fetal bovine serum, 4 mM L-glutamine, 4.5 g/liter glucose, 100 units/ml penicillin, and 100 g/ml streptomycin sulfate under a 5% CO 2 atmosphere at 37°C. MEG-01S cells were caused to differentiate by treatment with 12-O-tetradecanoylphorbol-13-acetate to express H-PGDS and COX-1, as described previously (50) .
After the cells had been cultured for 1 day, AT-56 was added to them at different doses ranging from 0 to 100 M, and the cells were then incubated at 37°C for 10 min. Thereafter, they were stimulated with a calcium ionophore, A23187 (5 M), at 37°C for 15 min. The culture media were harvested and centrifuged at 10,000 ϫ g for 5 min to remove the cells, and the supernatant was removed and stored at Ϫ80°C until the measurements of PGs could be made. In some experiments, these cells were prelabeled with [1- 14 C]arachidonic acid (3.7 kBq/ well) for 12 h before the assay. PGD 2 , PGE 2 , and PGF 2␣ in the culture medium were quantified as described below.
PG Production by Stab Wound Brain Injury-The protocols used for all animal experiments in this study were approved by the Animal Research Committee of the Osaka Bioscience Institute.
H-PGDS KO mice (14 -16-week-old males or females weighing 25-30 g, C57BL/6 strain) (2, 51) containing only L-PGDS were used for the stab injury model of the brain. AT-56 of various doses (1, 3, 10, and 30 mg/kg body weight) was administered orally to H-PGDS KO mice 1 h before the stab wound injury. Under pentobarbital (50 mg/kg) anesthesia, a 25-gauge needle was inserted into the frontal cortex of the brain of H-PGDS KO mice at a position 2 mm caudal to the bregma, 2 mm lateral to the sagittal suture, and 1 mm deep. After the needle had been withdrawn, the brains were harvested, immediately frozen in liquid nitrogen, and stored in a deep freezer (Ϫ80°C) until the measurements of PG contents could be made.
Measurement of PG Contents-The amounts of PGs in the cell culture media and brain tissues were determined as described previously (22) . In brief, the cell culture media and the frozen brain tissues were homogenized in ethanol containing 0.02% HCl at pH 2.0 and (22)) were actively sensitized by an intraperitoneal injection of 10 g of ovalbumin (Sigma) in 0.2 ml of aluminum hydroxide gel (Serva, Heidelberg, Germany) on days 0 and 14 and then exposed to aerosolized ovalbumin (50 mg/ml in sterile saline) for 20 min on day 21 (52) . At 2 days after the ovalbumin challenge, the bronchoalveolar lavage fluid was collected as reported previously (52) . Total and differential cell counts (500 cells) were obtained based on standard morphologic criteria after the cells had been cytospun onto glass slides and stained with Diff-Quik (Dade Diagnostics).
Pharmacokinetics of AT-56-Male C57BL/6 mice (7 weeks old, weighing 22-26 g; Japan SLC, Shizuoka, Japan) were given a single oral dose of 10 mg/kg AT-56 or a single intravenous dose of 2 mg/kg AT-56. Plasma was collected after euthanasia from 3 mice/group at 30 min and 1, 2, 4, 8, and 24 h for oral administration and 5 and 30 min and 1, 2, 4, 8, 12, and 24 h after intravenous dosing. Whole blood sample was collected into a heparinized syringe at each time point. Plasma was obtained by centrifugation and was stored at Ϫ30°C until analysis.
Concentrations of AT-56 in plasma were determined by high performance liquid chromatography coupled to mass spectrometry. Samples were separated by chromatography with a Cadenza HS-C18 column (2 mm ϫ 150 mm; Imtact Corp., Kyoto, Japan) at a column temperature of 33°C with a 5-90% acetonitrile gradient in 0.02% formic acid at a flow rate of 0.2 ml/min for 12 min. Injection volume was 10 l. AT-56 was detected by mass spectrometry with the system (Waters Associates) composed of the 2695 separation module, 996 photodiode array detector, and ZQ-4000 mass spectrometry detector with an electrospray ionization source. The electrospray ionization interface was operated at a source temperature of 115°C and a desolvation temperature of 350°C. Cone gas and desolvation gas flow were 124 and 606 liters/h, respectively. Cone voltage for AT-56 was positive 33 V for m/z ϭ 398. Pharmacokinetic parameters were calculated using noncompartmental analysis with WinNonlin, version 5.0.1 (Pharsight, Mountain View, CA).
Statistics-Comparisons were analyzed for statistical significance by Dunnett's multicomparison test using SigmaPlot (Systat Software, CA). p Ͻ 0.05 was considered significant.
RESULTS

Inhibition of the L-PGDS Activity by AT-56-AT-56
inhibited the PGDS activity of both ␤-trace purified from human CSF and purified recombinant mouse L-PGDS C89A/C186A mutant in a concentration (10 -250 M)-dependent manner. The L-PGDS activity of both preparations was inhibited to 30% with 250 M AT-56, and the IC 50 value was calculated to be 95 M. However, the activities of the purified COX-1, COX-2, m-PGES-1, or H-PGDS in the arachidonate cascade were not significantly affected by AT-56 up to 250 M (Fig. 2A) .
Kinetic experiments revealed that AT-56 inhibited the recombinant L-PGDS in a competitive manner against the substrate PGH 2 , as shown in Lineweaver-Burk plots (Fig. 2B) , in which the V max value remained unchanged but the K m value increased when the AT-56 concentration was increased (0 -120 M). The apparent K i value of AT-56 was calculated to be 75 M, which was 5.3-fold higher than the K m value of the L-PGDS activity for PGH 2 (14 M) in the presence of 10% DMSO.
Binding Interaction between L-PGDS and AT-56 Analyzed by NMR-We have previously determined the NMR structure of the mouse L-PGDS C89A/C186A mutant (49) . The interaction sites of L-PGDS with AT-56 were determined by the chemical shift perturbation method (53) based on the two-dimensional 1 H-15 N heteronuclear single quantum correlation NMR spectra of L-PGDS after the successive addition of AT-56 (Fig. 3) . Upon AT-56 binding, large changes (Ͼ0.08 ppm) of chemical shift were observed at several amino acid residues of L-PGDS (i.e. Ser 52 , Thr 80 , Met 94 , and His 116 ) (Fig. 3A) . These residues are located at the upper part of the central cavity of the ␤-barrel structure of the L-PGDS molecule (Protein Data Bank code 2E4J; Fig. 3B (Fig.  4A ) in a concentration-dependent manner, and the fluorescence intensity was decreased to about 60% in the presence of 10 M AT-56. On the other hand, the W54A/C89A/C186A mutant showed about 60% of the tryptophan fluorescence of the C89A/C186A mutant in the absence of AT-56 and did not show the fluorescence quenching in the presence of 10 M AT-56 (Fig. 4A) . The C89A/C186A mutant showed fluorescence quenching by the addition of 13-cis-retinoic acid in a concentration-dependent manner, with the fluorescence intensity being decreased to about 8% in the presence of 10 M 13-cis-retinoic acid (Fig. 4B) . The C89A/C186A mutant in the presence of 10 M AT-56 and the W54A/C89A/C186A mutant showed about 60% of the fluorescence intensity of the C89A/ C186A mutant in the absence of 10 M AT-56. In both cases, the fluorescence intensity was decreased by the addition of 13-cis-retinoic acid in a concentration-dependent manner to Ͻ10% in the presence of 10 M 13-cis-retinoic acid, giving the same fluorescence quenching curves even in the presence of 10 M AT-56. These results indicate that AT-56 binds near Trp 54 in the AB-loop of L-PGDS but not to the Trp 43 residue in the retinoid-binding pocket, being consistent with the results obtained by NMR titration analysis.
Inhibition of PGD 2 Production in L-PGDS-expressing Human Medulloblastoma TE-671 Cells by AT-56-Human medulloblastoma TE-671 cells constitutively express L-PGDS (54).
We pretreated TE-671 cells for 10 min with 0 to 30 M AT-56, stimulated them with calcium ionophore A23187 (5 M) at 37°C for 15 min, and then determined the production of PGD 2 , PGE 2 , and PGF 2␣ by enzyme immunoassay to investigate the effects of AT-56 on PG production by these cells. AT-56 dosedependently inhibited the production of PGD 2 without affecting the production of PGE 2 and PGF 2␣ (Fig. 5A) .
Dose-dependent inhibition of the A23187-induced PGD 2 production by AT-56 (3-100 M) was also confirmed by using [1- 14 C]arachidonic acid-prelabeled TE-671 cells (Fig. 5B) . However, the production of other 14 C-labeled metabolites was not inhibited by AT-56 up to 100 M. Moreover, AT-56 had no effect on the production of PGD 2 by human H-PGDS-expressing MEG-01S cells (50) . H-PGDS-specific inhibitor, HQL-79, inhibited PGD 2 production from MEG-01S cells but not from TE-671 cells. These results indicate that AT-56 selectively inhibits PGD 2 production catalyzed by L-PGDS without affecting the production of other prostanoids. L-PGDS in all of their organs (51) . In a stab wound brain injury model, the PGD 2 content in the brain of the wounded H-PGDS KO mice (118 Ϯ 22 ng/brain) was significantly increased as compared with that of the control mice without injury (0.23 Ϯ 0.04 ng/brain). When various doses of AT-56 were administered orally 1 h before the injury, the total amount of PGD 2 in the brain decreased dose-dependently to 40% with 30 mg/kg AT-56 (Fig. 6A) . The amounts of PGE 2 and PGF 2␣ in the brain were not significantly changed in any conditions (Fig. 6A) . These results indicate that orally administered AT-56 inhibited the L-PGDS reaction in the brain.
Suppression of PGD 2 Production in the Stab-wounded Brain by Oral Administration of AT-56-To
Suppression of L-PGDS-mediated Allergic Airway
Inflammation by AT-56-We next evaluated the therapeutic effect of AT-56 on PGD 2 -mediated lung inflammation. Human L-PGDS TG mice were used in an OVA-induced lung inflammation model (52) . The numbers of total cells and infiltrating eosinophils and monocytes in the bronchoalveolar lavage fluid of the L-PGDS TG mice were dose-dependently decreased to 75, 50, and 96% (actual numbers: 8.7 Ϯ 1.9, 2.53 Ϯ 0.73, and 6.16 Ϯ 1.14 ϫ 10 4 cells/ml for total cells, eosinophils, and monocytes, respectively) in 1 mg/kg AT-56-treated mice and to 23, 6 , and 41% (2.7 Ϯ 0.4, 0.31 Ϯ 0.14, and 2.59 Ϯ 0.3 ϫ 10 4 cells/ml, respectively) in 10 mg/kg AT-56-treated ones compared with the numbers for the vehicle-administered mice (11.6 Ϯ 1.6, 5.28 Ϯ 1.37, and 6.36 Ϯ 0.72 ϫ 10 4 cells/ml, respectively) (Fig. 6B ). These results demonstrate that AT-56 prevented the eosinophil infiltration by inhibiting transgened human L-PGDS in vivo.
Pharmacokinetic Properties of AT-56-We also determined pharmacokinetic properties of AT-56. Fig. 7 shows the time courses of the plasma concentration of AT-56 after an oral administration to mice at a dose of 10 mg/kg and an intravenous bolus injection of 2 mg/kg. Table 1 summarizes pharmacokinetic parameters of AT-56. After the oral administration, the plasma level of AT-56 reached the maximum (2.15 g/ml) within 30 min and decreased with time to be lower than the detection limit (0.4 ng/ml) at 12 h after the administration. The area under the concentration-time curve was calculated to be 2.18 and 8.95 g/ml ϫ h after the intravenous administration of 2 mg/kg and the oral administration of 10 mg/kg, respectively. Based on these data, bioavailability of AT-56 was calculated to be 82%, indicating that orally administered AT-56 was well absorbed in mice.
DISCUSSION
In the present study, we demonstrated that AT-56 is an orally active inhibitor specific for L-PGDS with a high bioavailability. The results of the kinetic analyses indicated that AT-56 was a competitive inhibitor against the substrate, PGH 2 . NMR titration analysis revealed that AT-56 bound to the catalytic pocket of L-PGDS, in which the catalytic center Cys 65 is located (49) Our data demonstrate that AT-56 inhibited the isomerization reaction of PGH 2 to PGD 2 catalyzed by L-PGDS in a competitive manner against PGH 2 with a K i value of 75 M (Fig. 2) , which was 5.3-fold higher than the K m value of the L-PGDS activity for PGH 2 (14 M) in the presence of 10% DMSO. Therefore, in the enzyme assay, AT-56 inhibited the enzyme activity clearly in a high concentration range in the presence of PGH 2 . On the other hand, in the absence of PGH 2 , AT-56 binds to the enzyme and induces the fluorescence quenching even in the low concentration range. Various inorganic selenium compounds are also known to inhibit both the purified L-PGDS and the enzyme in the crude brain supernatant in a noncompetitive manner with a K i value of 10 M (40). The K i value of AT-56 was 7.5-fold higher than that of SeCl 4 . However, the inhibition mode of AT-56 was quite different from that of selenium; i.e. this is the first competitive inhibitor of L-PGDS against PGH 2 to be reported. When the same dose of various seleno-compounds was used in cell cultures, such compounds reduced PGD 2 production; however, their efficacy cannot be attributed solely to the effects on the PGD 2 pathway. Seleno-compounds also inhibited the release of arachidonic acid and the production of all PGs due to the lack of specificity of action. In contrast, when human TE-671 cells were stimulated with the Ca 2ϩ ionophore A23187 in the presence of 10 M AT-56, only a base level of PGD 2 biosynthesis was observed without changing the arachidonic acid release (Fig. 5B) .
At present, the reason why the IC 50 value in the cell was lower than the IC 50 and K i values for purified L-PGDS is unknown. L-PGDS requires sulfhydryl compounds, such as reduced GSH, dithiothreitol, or ␤-mercaptoethanol, for its catalytic reaction, although it catalyzes the isomerization of the substrate PGH 2 to the product PGD 2 . The endogenous sulfhydryl compounds have not been identified in its reaction, and GSH or dithiothreitol have been used as a reductant in in vitro experiments. In this present study, we used GSH for the enzyme inhibition assay of AT-56. Thus, it is possible that the reductant for the L-PGDS reaction is different from the endogenous one. It might be also possible that L-PGDS requires some other cofactor for its catalysis. AT-56 might effectively inhibit the L-PGDS reaction in the presence of such endogenous cofactor.
Recently, we demonstrated that L-PGDS produced PGD 2 coupled with COX-2 in TE-671 cells (43) . L-PGDS coupled to COX-2 may be more sensitive to AT-56 than L-PGDS itself. Since AT-56 is a relatively lipophilic compound, its local concentration around the L-PGDS-COX-2 complex within endoplasmic reticulum may be high enough to efficiently inhibit the production of PGD 2 within the cell.
Although both L-PGDS and H-PGDS became evolutionarily diversified from quite different ancestor gene families (38, 39) , these enzymes can catalyze the same isomerization reaction. HQL-79 recently has been identified as an H-PGDS inhibitor. In this study, we found that AT-56, which is an HQL-79-derivative compound, also has an inhibitory activity against the L-PGDS reaction both in vitro and in vivo, suggesting that the active site architecture for the substrate binding and the catalytic reaction mechanism of L-PGDS could be similar to those of H-PGDS.
Here, we demonstrated pharmacologically and biochemically that AT-56 is an orally effective inhibitor selective for L-PGDS. Especially, it should be noted that AT-56 specifically inhibited the production of PGD 2 catalyzed by L-PGDS but only marginally affected the production of other prostanoids. In this sense, AT-56 is an even better PGD 2 -blocking compound than inorganic selenium compounds. Earlier we demonstrated that PGD 2 produced by L-PGDS regulates physiological sleep (1) and pain (7) and also that L-PGDS acts as an extracellular transporter for various useful or harmful hydrophobic compounds (34 -36) . Thus, AT-56 may be predicted to selectively suppress the drowsiness or pain reaction mediated by L-PGDScatalyzed PGD 2 without showing the various side effects caused by the suppression of cytoprotective and anti-inflammatory PGs.
We did not detect any acute toxic effects of AT-56 after its oral administration even at a dose of 100 mg/kg. AT-56 possesses a direct and previously unknown inhibitory effect on L-PGDS in vitro and in vivo, suggesting that AT-56 might be a useful prototypic molecule to develop selective and/or nonselective inhibitors for L-PGDS and H-PGDS, which may act as anti-somnolence and anti-inflammatory drugs, respectively. The development of such selective and nonselective inhibitors of both enzymes would be helpful to determine the role of PGD 2 in animal models. Such inhibitors would be drug candidates or actual drugs. 
